The retina contains specialized photoreceptor cells known as rods and cones. Rods are responsible for vision in low-light conditions, while cones support daytime and color vision. In dogs affected by BBS2-PRA, these photoreceptor cells gradually lose their function and die, reducing the retina’s ability to process visual information. The disease is progressive, meaning that vision loss worsens over time and cannot be reversed once retinal damage has occurred.
The earliest signs of BBS2-PRA often involve night blindness, as rod cells are typically affected first. Owners may notice that their dog becomes hesitant in dimly lit environments, struggles to navigate at night, or bumps into objects in low-light conditions. As the disease advances and cone cells become affected, daytime vision also begins to decline. Dogs may show difficulty locating toys, recognizing obstacles, or moving confidently in unfamiliar surroundings. In advanced stages, complete blindness can occur. Although the condition leads to significant vision loss, it is generally not painful, and many dogs adapt well to their changing visual abilities with proper support and environmental adjustments.
The BBS2-PRA DNA Health Test is designed to detect the specific genetic mutation associated with this inherited retinal disease. Testing is straightforward and typically requires a cheek swab or blood sample. The sample is analyzed in a specialized laboratory to determine whether the dog carries the BBS2 mutation. Because the test evaluates DNA directly, it can be performed at any age, including in puppies before clinical signs develop.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the BBS2-PRA mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is not expected to develop the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a high likelihood of developing BBS2-related Progressive Retinal Atrophy during its lifetime.
Genetic testing for BBS2-PRA provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed mating decisions that help reduce the occurrence of the disease while maintaining genetic diversity within the breed. Avoiding the breeding of two carrier dogs significantly decreases the risk of producing affected puppies.
For dog owners, knowing a dog’s genetic status allows for proactive eye health monitoring and regular veterinary ophthalmic examinations. While there is currently no cure to stop or reverse retinal degeneration caused by BBS2-PRA, early identification helps owners prepare for future vision changes and provide appropriate support throughout the dog’s life.
The Progressive Retinal Atrophy (BBS2-PRA) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine eye health, and helps reduce the impact of this inherited cause of blindness. Through early detection and informed breeding strategies, breeders and owners can contribute to healthier future generations of dogs.
